AIM AIM ImmunoTech Inc
Company Analysis
Latest News
🔴 AIM ImmunoTech is trading 15% down today with no clear catalyst identified
AIM ImmunoTech is trading 15% down at $0.22 after no clear company-specific catalyst was identified for August 14, 2026. - Recent coverage focused on August...
🔴 AIM ImmunoTech is trading 5.5% down today with no clear company-specific catalyst
AIM ImmunoTech is trading 5.5% down at $0.24, with no clear company-specific announcement dated August 14, 2026 explaining the decline. - Recent coverage...
AIM ImmunoTech Inc Q2 2026 Earnings Preview: What Analysts Expect on August 13, 2026
AIM ImmunoTech is expected to report a Q2 2026 loss of $0.17 per share on minimal revenue of approximately $0.03 million, with its $0.28 stock price currently...
🔴 AIM ImmunoTech is trading 5.36% down today after $3.8 million Q2 loss misses consensus
AIM ImmunoTech is trading 5.36% down now at $0.25 after its August 10, 2026, second-quarter results showed a $3.8 million net loss and EPS of $(0.43), missing...
AIM CEO Publishes Article Highlighting Ampligen's Potential as Biodefense Therapeutic
AIM ImmunoTech disclosed that its CEO, Thomas K. Equels, published an article in the online media outlet Breaking Defense. The article advocates for the...
🔴 AIM ImmunoTech is trading 5% down today after a $3.8 million Q2 net loss
AIM ImmunoTech is trading at $0.27, down -5.05%, after second-quarter results showed a $3.8 million net loss. - The company reported $9.9 million in cash and...
AIM ImmunoTech Posts Wider Losses on Thin Revenue — Can $9.9 Million in Cash Buy Enough Time?
Shares of AIM ImmunoTech slid 7.5% to $0.26 after the micro-cap biotech reported second-quarter results that showed a familiar pattern: negligible revenue,...
🔴 AIM ImmunoTech is trading 7.5% down in pre-market after net loss widened to $3.79 million
AIM ImmunoTech is trading 7.53% down in pre-market at $0.26 after reporting second-quarter results on August 7, 2026, which showed a net loss of $3.79...
Aim ImmunoTech second quarter 2026 cash reaches $9.9M as pancreatic cancer trial enrollment concludes
Aim ImmunoTech reported a second quarter 2026 net loss of $3.8 million, or $0.43 per share, while significantly improving its liquidity position. The company...
AIM ImmunoTech Returns to Positive Equity, But Flags 'Going Concern' Risk
AIM ImmunoTech reported positive stockholders' equity of $7.7 million as of June 30. This was included in its second-quarter 2026 report. The company...
🔴 AIM ImmunoTech is trading 5% down today in a speculative, technically driven move
AIM ImmunoTech is trading at $0.27, down -5.01% in a speculative, technically driven move. - The decline reverses part of its 7.83% gain from August 5, 2026,...
🟢 AIM ImmunoTech is trading 8.9% up today on continued biotech momentum and speculative interest
AIM ImmunoTech is trading at $0.30 (8.9%) up in after-hours trading, extending a multi-day rebound fueled by broader biotech sector strength and speculative...
🟢 AIM ImmunoTech is trading 11% up today on sector momentum and speculative trading
AIM ImmunoTech is trading 11% up today at $0.29 as the stock extends a sharp multi-day rebound driven by broader biotech sector strength and speculative...
🟢 AIM ImmunoTech is trading 5.7% up today amid sector momentum and speculative trading
AIM ImmunoTech is trading 5.7% up today at $0.28 amid broader sector momentum and a lack of company-specific news. • The stock is extending a volatile...
🟢 AIM ImmunoTech is trading 10.7% up today on a light-liquidity rebound after recent weakness
AIM ImmunoTech is trading 10.7% up at $0.26 on what appears to be a light-liquidity rebound following recent weakness. • The move occurs in the absence of...
🟢 AIM ImmunoTech is trading 5.9% up today on a light-liquidity bounce despite no news
AIM ImmunoTech is trading 5.9% up at $0.25 on a light-liquidity bounce despite no fresh news or fundamental catalysts. • The move follows several choppy,...
🟢 AIM ImmunoTech is trading 6.4% up today in a light-liquidity pre-market move with no clear catalyst
AIM ImmunoTech is trading at $0.25 (6.4% up) in pre-market, bouncing modestly after several sessions of low-priced, choppy trading with no clear fundamental...
🔴 AIM ImmunoTech is trading 6.8% down today on broader biotech sector pressure
AIM ImmunoTech is trading at $0.23 (-6.76%) following a weak start to the session, likely driven by broader risk-off pressure in the biotech and small-cap...
🔴 AIM ImmunoTech is trading 5.6% down today after shareholder approval of a reverse split and dilutive share issuance
AIM ImmunoTech is trading at $0.24 (5.6% down) as investors continue to react to shareholder approval of a reverse stock split and significant dilutive share...
🔴 AIM ImmunoTech is trading 5% down today after shareholder approval of reverse split and dilutive share issuances
AIM ImmunoTech is trading 5% down at $0.26 following shareholder approval of a potential reverse stock split and significant new share issuances tied to...